{
    "organizations": [],
    "uuid": "24444db3ead7edee0e85ffcfb8fc91067b675a0f",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-gw-pharmaceuticals-announces-ema-a/brief-gw-pharmaceuticals-announces-ema-accepts-epidiolex-marketing-authorization-application-for-review-idUSFWN1PV15N",
    "ord_in_thread": 0,
    "title": "BRIEF-GW Pharmaceuticals Announces EMA Accepts Epidiolex Marketing Authorization Application For Review",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 5 (Reuters) - Gw Pharmaceuticals Plc:\n* GW PHARMACEUTICALS ANNOUNCES THE EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS EPIDIOLEX® (CANNABIDIOL) MARKETING AUTHORIZATION APPLICATION (MAA) FOR REVIEW\n* GW PHARMACEUTICALS PLC - ‍OUTCOME OF MAA REVIEW BY EMA IS EXPECTED IN Q1 2019​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-06T05:05:00.000+02:00",
    "crawled": "2018-02-06T23:50:39.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "gw",
        "pharmaceutical",
        "plc",
        "gw",
        "pharmaceutical",
        "announces",
        "european",
        "medicine",
        "agency",
        "ema",
        "accepts",
        "cannabidiol",
        "marketing",
        "authorization",
        "application",
        "maa",
        "review",
        "gw",
        "pharmaceutical",
        "plc",
        "maa",
        "review",
        "ema",
        "expected",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}